Search

Displaying results 6501 - 6510 of 8195 in total
  1. Drug

    Apazunersen

    go.drugbank.com/drugs/DB16981
    Investigational

    Apazunersen is an antisense oligonucleotide designed to target and inhibit the expression of UBE3A-AS. It is being investigated for the treatment of Angelman Syndrome.[L46772]

  2. Drug

    GS-9191

    go.drugbank.com/drugs/DB15084
    Investigational

    GS-9191 is under investigation in clinical trial NCT00499967 (Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts).

    Categories: P-glycoprotein inhibitors
  3. Drug

    Sisunatovir

    go.drugbank.com/drugs/DB15674
    Investigational

    Sisunatovir is under investigation in clinical trial NCT04267822 (Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV).

  4. Drug

    AZD2315

    go.drugbank.com/drugs/DB06540
    Experimental

    The drug AZD2315, an immunosuppressant developed by AstraZeneca, was in Phase 1 clinical trials for the treatment of rheumatoid arthritis but was discontinued during this phase

  5. Drug

    Apitegromab

    go.drugbank.com/drugs/DB16096
    Investigational

    Apitegromab is under investigation in clinical trial NCT03921528 (An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy).

  6. Drug

    N-acetyl-alpha-neuraminic acid

    go.drugbank.com/drugs/DB03721
    Experimental

    An N-acyl derivative of neuraminic acid. N-acetylneuraminic acid occurs in many polysaccharides, glycoproteins, and glycolipids in animals and bacteria. (From Dorland, 28th ed, p1518)

    Synonyms: N-Acetyl-alpha-D-neuraminic acid
  7. Drug

    ATX-F8-117

    go.drugbank.com/drugs/DB17712
    Experimental

    ATX-F8-117 is an investigational peptide derived from Factor VIII. Developed by Apitope, it is being investigated for the treatment of hemophilia A.[L46163]

  8. Drug

    BHV-5000

    go.drugbank.com/drugs/DB17817
    Experimental

    BHV-5000 is an orally bioavailable, low-trapping, potent N-methyl-D-aspartate (NMDA) receptor antagonist. The active metabolite of BHV-5000 is [lanicemine].[L46446]

  9. Drug

    Brazikumab

    go.drugbank.com/drugs/DB16115
    Investigational

    Brazikumab is under investigation in clinical trial NCT03759288 (An Active and Placebo-controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease).

  10. Drug

    Foralumab

    go.drugbank.com/drugs/DB16170
    Investigational

    Foralumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).